Develop therapeutics from natural products to address unmet needs in neurological diseases like epilepsy. Success with drugs that treat a range of catastrophic, Orphan epilepsies like Infantile Spasms and Lennox Gastaut Syndrome, Insero intends a therapy for Dravet Syndrome to become its first clinical candidate compound. The company has used recent, molecular learning to screen and develop compounds which control seizures in animal models of Dravet.
Develop therapeutics from natural products to address unmet needs in neurological diseases like epilepsy
Genomic Expression develops Next Generation diagnostics to guide health professionals to more individually effective patient treatments. Pioneering gene sequencing and unique access to the biological samples of Rx and Dx companies will create a pipeline of Next Generation Diagnostics. Genomic Expression’s hypothesis-free platform will transforms biomarker discovery from a fishing expedition into a math discipline capable of delivering proof of concept of RNA diagnostics in a matter of months.
Develop Next Generation diagnostics to guide health professionals to more individually effective patient treatments
Developing recombinant human Leptin as a therapy for Alzheimer's Disease (AD) and as a preventative for those at risk. The human hormone and protein Leptin has a large number of receptors in the brain’s memory centers. The protein’s levels often decline in AD patients, and their cognitive deterioration correlates strongly with a decrease in Leptin circulation. The protein is neuroprotective, improves cognition and Neurotez expects it to reduce the pathological hallmarks of Alzheimer’s disease – plaques and tangles. Leptin replacement therapy represents a relatively risk-reduced approach to drug development.
Developing a recombinant human Leptin therapy for Alzheimer's Disease and as a preventative for those at risk
This proprietary device allows safe, in-office treatment of middle ear infections that affects 28M people in the US every year. 80% of all children under the age of three suffer from this ailment, and current U.S. CPT reimbursement represents a $4 billion domestic opportunity. Worldwide, the potential rises to $40 billion for the disposable component of Entra Tympanic’s EToscope™.
Device allows safe, in-office treatment of middle ear infections that affects 28M people in the US every year
Rapidly develop more effective, individualized therapies for people with epilepsy and other neurological disorders. Focusing on genetically-based epilepsies, Intellimedix designs and applies innovative technologies and models to identify new protocols. It repurposes existing drugs and seeks out new compounds that can personalize disease treatment.
Rapidly develop more effective, individualized therapies for people with epilepsy and other neurological disorders
Noninvasive technology for early detection and monitoring of Alzheimer's disease affecting 5.4M Americans. DiamiR develops proprietary noninvasive tests based on analysis of organ-enriched microRNAs in blood for early discovery of Alzheimer’s, other neurodegenerative diseases and cancer. In January 2014, the company announced validation of promising microRNA biomarkers for Mild Cognitive Impairment, an early stage of dementia including Alzheimer’s disease.
Noninvasive technology for early detection and monitoring of Alzheimer's disease affecting 5.4M Americans
AblaCor’s proprietary ablation catheter technology offers more effective treatment of atrial fibrillation (AF). The progressive impact of AF affects an estimated 6M people in the US and tens of millions worldwide. While traditional Pulmonary Vein Isolation for AF often requires repeated procedures, AblaCor’s CircumBlator™ maximizes ablator-tissue contact for a one-touch solution.
Proprietary ablation catheter technology offers more effective treatment of atrial fibrillation (AF)
Developing a therapeutic using perillyl alcohol for intranasal treatment of brain-related and respiratory cancers. Currently, drug delivery to the brain and spinal cord requires oral or intravenous administration. In all such systemic approaches, the blood brain barrier significantly hampers efficacy. Nasal brain delivery bypasses this inhibitor with direct, non-invasive access. NeOnc Technologies (NTI) is working in partnership with a pharmaceutical company to conduct a Phase I/II trial on their lead compound NEO100, for patients suffering recurrent, malignant gliomas.
Developing a therapeutic using perillyl alcohol for intranasal treatment of brain-related and respiratory cancers
Our online marketplace introduces you to private companies looking to transform healthcare. By expanding the number of accredited investors a private company can have, the JOBS Act makes these investment opportunities available at lower minimums.
Watch CEO Greg Simon Explain the Importance of Poliwogg, the Crowd and Investing in Young Healthcare Companies - July 6, 2013
Welcome to Poliwogg, an innovative financial firm transforming healthcare investing. We provide pathways for accredited investors to invest in early stage companies in health and life sciences, structure indexes that measure the impact of public companies in health, and are launching sector specific publicly registered venture funds focused by health vertical. Our mission is to transform...MORE
Investing in Health Care: Poliwogg's Greg Simon Explores What to Look For in an Early-Stage CompanyMORE
How Crowdfunding Could Revolutionize Health Care Investing: An Interview with Poliwogg's Greg SimonMORE
Eager to “democratize” healthcare investing, Poliwogg gives the crowd new ways to join inMORE
SoCalBio Elects Veteran Life Sciences Investor Joseph A. Boystak to Board of DirectorsMORE